These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9085304

  • 1. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain.
    Gourlay GK, Cherry DA, Onley MM, Tordoff SG, Conn DA, Hood GM, Plummer JL.
    Pain; 1997 Feb; 69(3):295-302. PubMed ID: 9085304
    [Abstract] [Full Text] [Related]

  • 2. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
    Gourlay GK.
    Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
    Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner JG, Stewart JH, Mount BM.
    Cancer; 1989 Jun 01; 63(11 Suppl):2275-83. PubMed ID: 2720576
    [Abstract] [Full Text] [Related]

  • 4. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain.
    Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J.
    J Pain Symptom Manage; 2002 Apr 01; 23(4):292-300. PubMed ID: 11997198
    [Abstract] [Full Text] [Related]

  • 5. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain.
    Broomhead A, Kerr R, Tester W, O'Meara P, Maccarrone C, Bowles R, Hodsman P.
    J Pain Symptom Manage; 1997 Aug 01; 14(2):63-73. PubMed ID: 9262035
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
    Ridgway D, Sopata M, Burneckis A, Jespersen L, Andersen C.
    J Pain Symptom Manage; 2010 Apr 01; 39(4):712-20. PubMed ID: 20413058
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design.
    Cundiff D, McCarthy K, Savarese JJ, Kaiko R, Thomas G, Grandy R, Goldenheim P.
    Cancer; 1989 Jun 01; 63(11 Suppl):2355-9. PubMed ID: 2720581
    [Abstract] [Full Text] [Related]

  • 8. Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration.
    Mignault GG, Latreille J, Viguié F, Richer P, Lemire F, Harsanyi Z, Stewart JH.
    J Pain Symptom Manage; 1995 Aug 01; 10(6):416-22. PubMed ID: 7561223
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.
    Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A.
    J Pain Symptom Manage; 2005 Jan 01; 29(1):80-90. PubMed ID: 15652441
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
    Moolenaar F, Meijler WJ, Frijlink HW, Visser J, Proost JH.
    Eur J Clin Pharmacol; 2000 Jun 01; 56(3):219-23. PubMed ID: 10952476
    [Abstract] [Full Text] [Related]

  • 11. Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily repro-dose morphine versus MST continus.
    Peat S, Sweet P, Miah Y, Barklamb M, Larsen U.
    Eur J Clin Pharmacol; 1999 Oct 01; 55(8):577-81. PubMed ID: 10541775
    [Abstract] [Full Text] [Related]

  • 12. Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients.
    Portenoy RK, Maldonado M, Fitzmartin R, Kaiko RF, Kanner R.
    Cancer; 1989 Jun 01; 63(11 Suppl):2284-8. PubMed ID: 2720577
    [Abstract] [Full Text] [Related]

  • 13. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients.
    Goughnour BR, Arkinstall WW, Stewart JH.
    Cancer; 1989 Jun 01; 63(11 Suppl):2294-7. PubMed ID: 2720578
    [Abstract] [Full Text] [Related]

  • 14. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine?
    Christrup LL, Sjøgren P, Jensen NH, Banning AM, Elbaek K, Ersbøll AK.
    J Pain Symptom Manage; 1999 Sep 01; 18(3):164-73. PubMed ID: 10517037
    [Abstract] [Full Text] [Related]

  • 15. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER, Pantaleon C, Iverson M, Aigner S.
    Adv Ther; 2019 Sep 01; 36(9):2394-2401. PubMed ID: 31278694
    [Abstract] [Full Text] [Related]

  • 16. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.
    Collins JJ, Geake J, Grier HE, Houck CS, Thaler HT, Weinstein HJ, Twum-Danso NY, Berde CB.
    J Pediatr; 1996 Nov 01; 129(5):722-8. PubMed ID: 8917240
    [Abstract] [Full Text] [Related]

  • 17. The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects.
    Kaiko RF, Grandy RP, Oshlack B, Pav J, Horodniak J, Thomas G, Ingber E, Goldenheim PD.
    Cancer; 1989 Jun 01; 63(11 Suppl):2348-54. PubMed ID: 2720580
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain.
    Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke AC.
    J Clin Pharmacol; 1995 Jul 01; 35(7):666-72. PubMed ID: 7560246
    [Abstract] [Full Text] [Related]

  • 20. Controlled-release oxycodone and morphine in cancer related pain.
    Heiskanen T, Kalso E.
    Pain; 1997 Oct 01; 73(1):37-45. PubMed ID: 9414055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.